News & Events
Insight TNBCtype™, the first and only CLIA-validated assay for triple negative breast cancer (TNBC) molecular subtyping, was featured in two posters on December 7 at the 2018 San Antonio Breast Cancer Symposium (SABCS).
The poster, “Impact of molecular subtypes on long term outcomes in triple negative breast cancer (TNBC) patients treated with adjuvant AC chemotherapy on SWOG S9313,” was presented by Priyanka Sharma, MD, Associate Professor of Medicine at the University of Kansas Medical Center. The poster explored the lack of known subtype-specific, long-term outcomes for TNBC patients who are treated with uniform adjuvant chemotherapy and aimed to identify and characterize these outcomes. The results underscored TNBC heterogeneity and the need to account for this factor in prospective clinical trials.
The poster presented by Hiroko Masuda, M.D., Ph.D., of Showa University, and Naoto Ueno, M.D., Ph.D., of MD Anderson Cancer Center analyzed TNBC morphology and the suggestion of apocrine carcinoma as a TNBC category. The poster, “Apocrine morphology and luminal androgen receptor (LAR) molecular subtype predict prognosis of patients with residual triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy,” concluded that the use of both morphology and genomic testing is significant to define prognosis in patients with apocrine tumors who have residual TNBC after carcinoma of non special type (NST).
The investigators use of Insight TNBCtype™ in their studies showcase the potential for molecular subtyping in TNBC assessment and treatment. Exclusively licensed from Vanderbilt University Medical Center, Insight TNBCtype™ is the first and only CLIA-validated and CAP-accredited assay with implications in the development of novel TNBC targeted therapeutics and diagnostics.